MFS混合研究新興市場股票主動型ETF BREE 深 滬
等待開盤 04-02 09:30:00 美东时间
22.765
+0.265
+1.18%
華盛通- 最 高22.85
- 今 開22.85
- 成交量 8541股
- 最 低 22.765
- 昨 收 22.50
- 總市值 1764.29万
- 52周最高 24.75
- 市盈率 靜 --
- 換手率 1.10%
- 52周最低 21.70
- 委 比 0.00%
- 總股本 77.50万
- 歷史最高 24.75
- 量 比 1.00
- 振 幅 0.38%
- 歷史最低 21.70
- 每 手 1
- 風險率 0.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Savara Receives European Medicines Agency Validation For Submission Of MOLBREEVI MAA In Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the EMA has validated the submission of the MOLBREEVI MAA in autoimmune PAP;
03-30 20:16
Logistea Wins Top BREEAM Rating for Nässjö Logistics Property
Logistea AB Class A ( ($SE:LOGI.A) ) has shared an update. Logistea AB, a Swedi...
03-30 18:52
Savara GAAP EPS of -$0.13
Savara press release (SVRA): Q4 GAAP EPS of -$0.13. Research and development expenses for the fourth quarter of 2025 and 2024 were $20.9 million and $23.3 million, respectively. General and administra...
03-14 03:28
Savara Inc. publishes corporate presentation on autoimmune pulmonary alveolar proteinosis and MOLBREEVI Phase 3 data
Savara Inc. publishes corporate presentation on autoimmune pulmonary alveolar proteinosis and MOLBREEVI Phase 3 data Savara released a corporate presentation outlining its focus on autoimmune pulmonary alveolar proteinosis, a rare lung disease caused by GM-CSF autoantibodies that impair surfactant c
03-13 20:20
Savara Q4 net loss widens as expenses rise
Savara Q4 net loss widens as expenses rise Overview US rare disease drug developer's Q4 net loss widened yr/yr as expenses rose General and administrative expenses increased due to workforce expansion and commercial planning Company achieved key regulatory milestones for MOLBREEVI in US and Europe O
03-13 20:15
Savara FY 2025 net loss widens 24% to USD 118.84 million as G&A expenses jump 68% to USD 42.06 million
Savara FY 2025 net loss widens 24% to USD 118.84 million as G&A expenses jump 68% to USD 42.06 million Savara reported a Q4 net loss of USD 32.24 million, or USD 0.13 per share. Research and development expenses in Q4 were USD 20.9 million, down 10%. General and administrative expenses in Q4 were US
03-13 20:10
Money Moves Abroad: Emerging Markets ETF Debuts As Investors Rotate Away From US Stocks
MFS launches a new active emerging markets ETF offering diversified exposure to developing economies across Asia, Latin America and beyond.
03-06 07:31
